Norway’s life science sector comprises 538 companies across biotechnology, medtech, digital health, pharma, investors, and supporting services. The 2026 Norway Life Science Trend Analysis, produced in partnership with The Life Science Cluster, highlights an ecosystem built on strong biotech foundations, growing digital health activity, and a pipeline concentrated in oncology and anti-infectives.
The ecosystem includes 185 biotech companies, 59 medtech firms, 80 digital health companies, and 31 investors. Biotech activity is led by therapeutics & diagnostics and R&D services, with small molecules, antibodies, and immunotherapy as the dominant modalities. Oncology accounts for the largest share of clinical assets (54), followed by infectiology/parasitology (11) and endocrinology (7). The pipeline spans all development stages, with 137 therapeutic assets available for out-licensing.
Financing activity reflects a maturing but selective market. Private equity rounds for life science companies totalled $130M in 2024, though 2025 saw a notable contraction to $8M, suggesting a tighter funding environment for Norwegian companies compared to Nordic peers such as Denmark ($467M) and Sweden ($486M) in 2025. The top 2025 private equity rounds were led by SonoClear AS ($4.47M) and Regenics AS ($3.21M). On the M&A front, Norway’s most notable 2024 deal was the acquisition of SpinChip Diagnostics AS by BioMérieux SA for $142.6M.
Looking ahead, Norway’s life science sector is supported by a robust early-stage pipeline, a strong university-linked research base, and the continued growth of its digital health and medtech segments, with significant opportunity to scale financing activity in line with broader Nordic trends.
For more detailed insights, request a free Biotechgate demo.
Download the Norway Trend Analysis Report 2026